

Change of Interim Results Date

Sep 12, 2022

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI and optical technology for faster and more accurate treatment decisions in wound care, announces that it will now release its interim results for the six months ended 30 June 2022 on Tuesday 20 September 2022.

Investor presentation

Wensheng Fan, Chief Executive Officer, and Nils Windler, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on Tuesday 20 September 2022 at 4.30 pm BST.

The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00 am BST the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Spectral MD here.

Investors who already follow Spectral MD on the Investor Meet Company platform will automatically be invited.

For further information please contact:

Spectral MD Holdings, Ltd. investors.spectralmd.com

Wensheng Fan, Chief Executive Officer via Walbrook PR

Nils Windler, Chief Financial Officer

SP Angel Corporate Finance LLP (NOMAD and Joint Broker)

Stuart Gledhill/Caroline Rowe (Corporate Finance)Vadim Alexandre/Rob Rees (Sales & Tel: +44 (0)20 3470 0470

Stifel Nicolaus Europe Limited (Joint Broker) Charles Hoare / Ben Maddison / Nick Harland Tel: +44 (0)20 7710 7600

/Will Palmer-Brown

Tel: +44 (0)20 7933 Walbrook PR Ltd (Media & Investor Relations)

8780 or spectralMD@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393 Paul McManus / Louis Ashe-Jepson

+44 (0)7407 804 654 Alice Woodings

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com